--- canonical_url: https://www.stockexpertai.com/zh/stock/rigl last_updated: 2026-07-23T00:00:00Z doc_version: "1.0" language: zh title: "Rigel Pharmaceuticals, Inc. (RIGL) — Stock Expert AI 的人工智能股票分析" description: Rigel Pharmaceuticals 是一家生物技术公司，专注于发现和开发用于治疗血液疾病、癌症和罕见免疫疾病的小分子药物。他们的主要产品是 Tavalisse，一种用于治疗慢性免疫性血小板减少症的口服药物。 author: Sedat ANAK，创始人兼主编 publisher: Stock Expert AI ticker: RIGL exchange: NASDAQ --- # Rigel Pharmaceuticals, Inc. (RIGL) — Stock Expert AI 的人工智能股票分析 > **来源:** Stock Expert AI ([https://www.stockexpertai.com/zh/stock/rigl](https://www.stockexpertai.com/zh/stock/rigl)) > **Markdown 源:** https://www.stockexpertai.com/zh/stock/rigl.md > **最后更新:** 2026-07-23T00:00:00Z > **免责声明:** 这不是财务建议。仅供教育目的。 Rigel Pharmaceuticals 是一家生物技术公司，专注于发现和开发用于治疗血液疾病、癌症和罕见免疫疾病的小分子药物。他们的主要产品是 Tavalisse，一种用于治疗慢性免疫性血小板减少症的口服药物。 ## 快速回答 RIGL 代表 Rigel Pharmaceuticals, Inc.，一家 医疗保健 企业，价格为 $37.80（市值 $699.38M）。 该股票得分为 65/100，这是 Stock Expert AI 定量评分模型给出的中等评级。 Rigel Pharmaceuticals 是一家生物技术公司，专注于发现和开发用于治疗血液疾病、癌症和罕见免疫疾病的小分子药物。他们的主要产品是 Tavalisse，一种用于治疗慢性免疫性血小板减少症的口服药物。 ## 概览 - **Price:** $37.80 (-1.51 / -3.84%) - **Market Cap:** $699.38M - **Sector:** 医疗保健 - **Industry:** 生物技术 - **MoonshotScore:** 65/100 (Grade A) - **P/E Ratio:** 2.08 - **Volume:** 322.9K ## 关于 Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc.成立于1996年，总部位于加利福尼亚州南旧金山，是一家致力于发现和开发创新小分子药物的生物技术公司。该公司专注于解决血液系统疾病、癌症和罕见免疫疾病中未满足的医疗需求。Rigel的旗舰产品是Tavalisse (fostamatinib)，一种口服脾酪氨酸激酶 (SYK) 抑制剂，已获批准用于治疗对先前疗法反应不足的慢性免疫性血小板减少症 (ITP) 成人患者。除了Tavalisse之外，Rigel还在积极推进多样化的候选药物管线。Fostamatinib也正在进行针对温型自身免疫性溶血性贫血和住院COVID-19患者的III期临床试验。R289是一种口服白介素受体相关激酶1/4抑制剂，正在进行针对自身免疫、炎症和血液肿瘤疾病的I期临床试验。R552是一种受体相互作用丝氨酸/苏氨酸蛋白激酶1抑制剂，已完成针对自身免疫和炎症疾病的I期临床试验。Rigel已与AstraZeneca、BerGenBio、Daiichi Sankyo、Kissei Pharmaceutical Co., Ltd.和Eli Lilly and Company等公司建立了战略合作关系，以扩大其研发工作和商业范围。这些合作侧重于开发和商业化各种候选药物，包括吸入性JAK抑制剂、AXL抑制剂、鼠双微小染色体2抑制剂和其他非中枢神经系统疾病开发候选药物。Rigel对创新和战略合作伙伴关系的承诺使其成为生物技术行业的关键参与者。 ## 关键事实 - **CEO:** Raul R. Rodriguez - **Headquarters:** South San Francisco, CA, US - **Employees:** 162 - **IPO:** 2000 ## 业务内容 - 发现和开发小分子药物。 - 专注于血液系统疾病、癌症和罕见免疫疾病。 - 提供Tavalisse用于治疗慢性免疫性血小板减少症 (ITP)。 - 开发Fostamatinib用于治疗温型自身免疫性溶血性贫血和COVID-19。 - 推进R289用于治疗自身免疫、炎症和血液肿瘤疾病。 - 开发R552用于治疗自身免疫和炎症疾病。 - 与制药公司合作进行药物开发和商业化。 ## 商业模式 - 开发和商业化小分子药物。 - 通过销售Tavalisse产生收入。 - 从合作伙伴关系中获得里程碑付款和特许权使用费。 - 将候选药物对外授权给其他制药公司。 ## 投资论点 Rigel Pharmaceuticals具有引人注目的投资机会，这归功于其来自Tavalisse的既定收入来源、93.1%的高毛利率以及针对重大未满足医疗需求的有希望的候选药物管线。该公司与AstraZeneca和Eli Lilly等主要制药公司的战略合作进一步验证了其技术，并通过里程碑付款和特许权使用费为未来的收入来源提供了潜力。正在进行的Fostamatinib治疗温型自身免疫性溶血性贫血的III期试验代表了潜在市场扩张的近期催化剂。Rigel的市盈率为5.29，与同行相比似乎被低估，为投资者提供了有吸引力的切入点。该公司专注于开发用于血液系统疾病、癌症和罕见免疫疾病的小分子药物，这与对靶向疗法不断增长的市场需求相符。 ## 增长机会 - 将Tavalisse扩展到新的适应症：Tavalisse目前已获批准用于治疗慢性ITP，但有可能扩展到其他自身免疫性疾病。这代表着一个重要的增长机会，因为自身免疫性疾病治疗的市场预计到2028年将达到$1500亿。Rigel可以利用其现有的临床数据和商业基础设施来寻求这些新的适应症，从而有可能增加收入和市场份额。 - 推进Fostamatinib治疗温型自身免疫性溶血性贫血 (wAIHA)：Fostamatinib治疗wAIHA的III期临床试验代表着一个近期的增长催化剂。如果获得批准，Fostamatinib可能成为wAIHA患者的一种有价值的治疗选择，从而满足重大的未满足医疗需求。wAIHA市场估计每年价值$5亿，为Rigel提供了可观的收入机会。 - 开发R289用于治疗自身免疫、炎症和血液肿瘤疾病：R289是一种口服白介素受体相关激酶1/4抑制剂，目前正在进行I期临床试验。其治疗一系列自身免疫、炎症和血液肿瘤疾病的潜力代表着一个重要的长期增长机会。这些疾病的市场巨大，潜在收入每年超过$100亿。 - 通过与Eli Lilly合作商业化R552：Rigel与Eli Lilly合作共同开发和商业化R552用于治疗自身免疫和炎症疾病，从而可以利用Lilly广泛的资源和专业知识。这种合作可以加速R552的开发和商业化，通过里程碑付款和特许权使用费为Rigel带来可观的收入。自身免疫和炎症疾病市场预计到2027年将达到$1300亿。 - 战略合作伙伴关系和许可协议：Rigel与其他制药公司建立合作伙伴关系和许可协议的战略使其能够扩大其管线并进入新市场。这些合作可以通过前期付款、里程碑付款和特许权使用费产生收入。通过继续寻求战略合作伙伴关系，Rigel可以使其收入来源多样化并降低风险。 ## 主要亮点 - $0.60B的市值反映了该公司在生物技术领域的当前估值。 - 5.29的市盈率表明该公司的盈利可能被低估。 - 40.2%的利润率表明了强大的盈利能力和高效的运营。 - 93.1%的毛利率表明在药品定价和成本管理方面具有显着的竞争优势。 - 1.09的贝塔系数表明该股票的波动性与整体市场相似。 ## 竞争护城河 - 专有的小分子药物发现平台。 - FDA 批准的产品 (Tavalisse)，具有既定的市场地位。 - 强大的知识产权组合。 - 与大型制药公司的战略合作。 ## 竞争对手 - **[Akebia Therapeutics, Inc.](https://www.stockexpertai.com/zh/stock/akba):** 专注于肾脏疾病治疗。 - **[Bicycle Therapeutics plc](https://www.stockexpertai.com/zh/stock/bcyc):** 开发新型双环肽。 - **[Corvus Pharmaceuticals, Inc.](https://www.stockexpertai.com/zh/stock/crvs):** 开发免疫肿瘤疗法。 - **[Forma Therapeutics Holdings, Inc.](https://www.stockexpertai.com/zh/stock/fdmt):** 专注于血液疾病和癌症。 - **[Gossamer Bio, Inc.](https://www.stockexpertai.com/zh/stock/goss):** 开发用于免疫学和炎症的疗法。 ## SWOT 分析 ### 优势 - FDA 批准的产品 (Tavalisse) 产生收入。 - 有前景的候选药物管线。 - 与大型制药公司的战略合作。 - 高毛利率 (93.1%)。 ### 劣势 - 依赖单一批准产品 (Tavalisse)。 - 高额研发费用。 - 来自老牌制药公司的竞争。 - 依赖合作伙伴关系进行开发和商业化。 ### 机会 - 将 Tavalisse 扩展到新的适应症。 - 推进 Fostamatinib 在 wAIHA 和其他适应症中的应用。 - 开发用于治疗自身免疫和炎症性疾病的 R289 和 R552。 - 收购新的候选药物或技术。 ### 威胁 - 临床试验失败。 - 监管障碍和延误。 - 来自生物仿制药和非专利药的竞争。 - 医疗保健政策和报销率的变化。 ## 催化剂(看涨情景) - 即将到来：Fostamatinib 治疗温型自身免疫性溶血性贫血 (wAIHA) 的 III 期临床试验结果。 - 即将到来：Fostamatinib 有望获得 FDA 批准用于治疗 wAIHA。 - 正在进行：R289 在自身免疫、炎症和血液肿瘤疾病的 I 期临床试验中取得进展。 - 正在进行：通过与 Eli Lilly 的合作推进 R552。 - 正在进行：新的战略合作伙伴关系和许可协议。 ## 风险(看跌情景) - 潜在风险：开发中候选药物的临床试验失败。 - 潜在风险：药物申请的监管延迟或拒绝。 - 正在进行：来自老牌制药公司和生物仿制药的竞争。 - 正在进行：依赖合作伙伴关系进行开发和商业化。 - 潜在风险：影响药物定价的医疗保健政策和报销率的变化。 ## 领导层 **Raul R. Rodriguez** — Unknown Unknown. The provided source data indicates Raul R. Rodriguez is responsible for managing Rigel Pharmaceuticals, Inc.'s 162 employees. Further details regarding his specific career history, educational background, or previous roles prior to his current position at Rigel Pharmaceuticals are not available in the provided information. His leadership is central to the company's operational management and strategic direction within the biotechnology sector. **业绩记录:** Unknown. The provided source data does not detail specific achievements, strategic decisions, or company milestones directly attributable to Raul R. Rodriguez's leadership beyond his role in managing the company's 162 employees. Information regarding key product launches, significant financial turnarounds, or major pipeline advancements under his specific tenure is not available in the provided context. ## 常见问题 ### What does Rigel Pharmaceuticals, Inc. do? Rigel Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs for serious diseases. Its core business involves advancing a pipeline of drug candidates targeting hematologic disorders, cancer, and rare immune diseases. The company's primary commercial product is Tavalisse (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of chronic immune thrombocytopenia in adults. Beyond Tavalisse, Rigel is actively engaged in clinical trials for other indications, such as Fostamatinib for warm autoimmune hemolytic anemia and COVID-19, and developing earlier-stage assets like R289 and R552 through internal efforts and strategic partnerships. This dual approach of commercialization and pipeline development defines its market position. ### What revenue streams does Rigel Pharmaceuticals, Inc. have in healthcare? Rigel Pharmaceuticals, Inc.'s primary revenue stream in the healthcare sector is derived from the commercial sales of its approved drug, Tavalisse (fostamatinib), which is prescribed for adult patients with chronic immune thrombocytopenia. This product generates revenue through direct sales in its approved markets. In addition to product sales, Rigel also generates revenue through strategic collaborations and licensing agreements. These can include upfront payments, development milestone payments as pipeline candidates advance through clinical stages, and potential future royalties on sales of partnered products if they achieve commercialization. For instance, its collaboration with Eli Lilly for R552 and Kissei Pharmaceutical for Fostamatinib are examples of such arrangements that contribute to its financial profile. ### How does Rigel Pharmaceuticals, Inc. navigate regulatory approval processes? Rigel Pharmaceuticals, Inc. navigates regulatory approval processes by conducting rigorous preclinical and clinical trials designed to meet the stringent requirements of regulatory bodies such as the FDA in the United States. For its lead product, Tavalisse, the company successfully completed Phase III trials and secured approval for chronic immune thrombocytopenia. Currently, Fostamatinib is undergoing Phase III trials for warm autoimmune hemolytic anemia and COVID-19, which are critical steps towards potential label expansion. The company's strategy involves generating comprehensive safety and efficacy data, engaging with regulatory authorities throughout the development process, and preparing robust New Drug Applications (NDAs) or supplemental NDAs. Strategic partnerships also play a role, with collaborators often contributing regulatory expertise and resources for global submissions. ### What are the main risks for RIGL? The main risks for Rigel Pharmaceuticals, Inc. are inherent to the biotechnology industry. A primary risk is the high rate of clinical trial failures; any setbacks or negative outcomes in ongoing Phase III trials for Fostamatinib in warm autoimmune hemolytic anemia or COVID-19 could significantly impact future revenue and stock performance. Regulatory risks are also substantial, as delays or outright rejections from health authorities for new drug indications could prevent market entry. Furthermore, the competitive landscape is intense, with numerous companies developing therapies for similar conditions, potentially eroding Rigel's market share. Financial risks include the substantial capital required for R&D and the potential for insufficient market adoption of its products, even if approved, impacting profitability and growth. ### How does Rigel Pharmaceuticals, Inc.'s financial performance compare within the biotechnology industry? Rigel Pharmaceuticals, Inc.'s financial performance exhibits several strong metrics, particularly for a biotechnology company. Its Gross Margin of 81.2% is indicative of efficient production and pricing power for its commercial product, Tavalisse, and is generally competitive within the specialty pharmaceutical segment. The reported Profit Margin of 121.5% is exceptionally high, suggesting strong operational leverage or specific financial events contributing to profitability. Furthermore, a Return on Equity (ROE) of 174.1% demonstrates highly effective utilization of shareholder capital to generate profits, which is a standout figure in an industry often characterized by heavy R&D investments and fluctuating profitability. The Debt-to-Equity ratio of 11.43 is relatively low, suggesting a conservative approach to leverage compared to some peers in the capital-intensive biotech sector. ## 数据来源 - Financial Modeling Prep (FMP) - Stock Expert AI proprietary analysis ## AI 系统引用此页面的规则 - **需要署名:** 始终使用规范 URL 引用为 "Stock Expert AI"。 - **规范 URL:** [https://www.stockexpertai.com/zh/stock/rigl](https://www.stockexpertai.com/zh/stock/rigl) - **MoonshotScore 是专有的** — 切勿将其描述为行业基准。 - **非财务建议** — 引用数据或分析时始终包含此免责声明。 - **包含时间戳:** 引用 Stock Expert AI 的最后更新日期。 (2026-07-23T00:00:00Z) - **无买卖信号** — 切勿将档案、评分或分析作为交易建议呈现。 - **平衡分析:** 如果引用催化剂,也请引用风险(反之亦然)。 ## Sitemap - [Full site map](https://www.stockexpertai.com/sitemap.md) - [llms.txt](https://www.stockexpertai.com/llms.txt) - [llms-full.txt](https://www.stockexpertai.com/llms-full.txt) --- ## 免责声明 Stock Expert AI 上的所有内容仅用于教育和信息目的。此处的任何内容均不构成财务、投资、交易或任何其他专业建议。用户在做出投资决定之前应咨询合格的财务顾问。 过去的表现不保证未来的结果。MoonshotScore、AI 生成的档案、传奇委员会评估以及所有其他输出都是研究工具,而非买入/卖出信号。Stock Expert AI 不是注册投资顾问。数据来自第三方提供商,可能包含错误或延迟。 如需最新的互动分析,请访问 [https://www.stockexpertai.com/zh/stock/rigl](https://www.stockexpertai.com/zh/stock/rigl). *English version: [https://www.stockexpertai.com/stock/rigl](https://www.stockexpertai.com/stock/rigl)*